Page 90 - Read Online

Saleh et al. J Cancer Metastasis Treat 2017;3:82-9 Journal of
DOI: 10.20517/2394-4722.2017.20
Cancer Metastasis and Treatment

www.jcmtjournal.com
Original Article Open Access

Combination of insulin-like growth factor-1,

IGF binding protein-3, chromogranin A and

prostate specific antigen can improve the

detection of prostate cancer

Saleh Ahmed Kamaleldin Saleh , Heba Mohamed Adly , Anmar Mohammed Nassir 2
1,3
1
1 Biochemistry Department, Faculty of Medicine, Umm Al Qura University, Al Awali, Makkah 24381, Saudi Arabia.
2 Department of Surgery, Faculty of Medicine, Umm Al Qura University, Al Awali, Makkah 24381, Saudi Arabia.
3 Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, Abasseya, Cairo 11591, Egypt.

Correspondence to: Dr. Saleh Ahmed Kamaleldin Saleh, Biochemistry Department, Faculty of Medicine, Umm Al Qura University, Al Awali,
Makkah 24381, Saudi Arabia. E-mail: Saleh-A-S@hotmail.com
How to cite this article: Saleh SAK, Adly HM, Nassir AM. Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and
prostate specific antigen can improve the detection of prostate cancer. J Cancer Metastasis Treat 2017;3:82-9.
ABSTRACT

Article history: Aim: Prostate cancer (PCa) is the second most prevalent male cancer worldwide and
Received: 13-03-2017 designated the sixth most frequent male cancer in Arab countries. Although prostate
Accepted: 26-04-2017 specific antigen (PSA) has become the best and most valuable biomarker for screening of
Published: 24-05-2017 PCa, elevated levels of PSA can reflect the presence of malignant cells but can overlap with
benign prostatic diseases. There is a necessity to develop and improve current tools for early
Key words: detection and diagnosis of PCa. This study was done to evaluate the validation of serum
Prostate cancer, insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), chromogranin A
benign prostatic hyperplasia, (CgA) and combination with PSA in treatment of benign prostatic hyperplasia (BPH) and
insulin-like growth factor-1, PCa patients. Methods: The study included 72 patients with PCa, 70 BPH patients and
IGF binding protein-3, 56 healthy male subjects of matched age. Full history and clinical data were recorded
chromogranin A
for all subjects. Results: Serum PSA attained sensitivity of 84% at 82% specificity with
an accuracy of 83%, although IGF-1, IGFBP-3 and CgA did not recognize PCa patients.
Conclusion: Combinations of IGF-1 and IGFBP-3 biomarkers with PSA were effectively
differentiated between PCa and control groups as well as improving the overall value of
sensitivity, specificity and diagnostic accuracy of PCa to 85% and 86% for IGF-1/PSA and
IGFP-3/PSA respectively.

INTRODUCTION The annual worldwide estimate is 1.1 million new
diagnosed PCa male patients, representing 15% of all
Prostate cancer (PCa) is ranked the second most male cancers and about 70% of the cases occurring
prevalent male cancer worldwide and is currently in developed countries. PCa represents the fifth most
[1]
the sixth frequent male cancer in Arab countries. common cause of male cancer death, accounting for
[2]
Quick Response Code:
This is an open access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work
non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: service@oaepublish.com

82 © 2017 OAE Publishing Inc. www.oaepublish.com